Looking at Wu Ting's expression, Zhang Heng finally understood what he meant.
A jolt went through him, and he asked in astonishment:
"Director Wu, are you saying that Pfizer's new drug, Sorafenib, causes cardiovascular and cerebrovascular events, and thrombotic diseases? No way. It passed the FDA certification and completed all three phases of clinical trials. If your theory is correct, there's no way this new drug could have been approved and brought to market..."
As he spoke, the realization slowly dawned on Zhang Heng, and his jaw dropped.
"Director Wu, this is no joke!"
Wu Ting smiled slightly and looked at Zhang Heng.
"I also hope my theory is wrong. But the fact is, Sorafenib does indeed have these kinds of problems."
Wu Ting pulled out the statistics on the patients Zhang Heng had been following up with, marking each case one by one.
